AN2 Therapeutics, Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
This is AN2 Therapeutics' 10-Q for the period ending June 30, 2026, filed on August 11, 2026. The filing document header contains only standard SEC metadata (CIK 0001880438, Delaware incorporation, pharmaceutical SIC code 2834) and does not disclose specific financial results, material contracts, significant transactions, counterparties, dollar amounts, share counts, or business developments in the excerpt provided. The actual operating results and material events are contained in the full 10-Q document (2.7M file size), which was not included in the text supplied.
Why this rating
Filing header only; no substantive facts disclosed. Full 10-Q contents unknown from text provided.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.